<DOC>
	<DOCNO>NCT00093652</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , work different way stop tumor cell divide stop grow die . Gefitinib may stop growth tumor cell block enzymes necessary growth . Radiation therapy use high-energy x-rays damage tumor cell . Combining oxaliplatin gefitinib radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose oxaliplatin give together gefitinib radiation therapy see well work treat patient locally advance metastatic esophageal cancer .</brief_summary>
	<brief_title>Oxaliplatin , Gefitinib , Radiation Therapy Treating Patients With Locally Advanced Metastatic Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose oxaliplatin administer gefitinib radiotherapy patient locally advance metastatic adenocarcinoma squamous cell carcinoma esophagus gastroesophageal junction . ( Phase I ) - Determine response rate patient treat regimen . ( Phase II ) Secondary - Determine time tumor progression median survival patient treat regimen . - Determine quality life patient treat regimen . - Determine safety regimen patient . OUTLINE : This phase I , open-label , dose-escalation study oxaliplatin follow phase II study . - Phase I : Patients receive oxaliplatin IV 2 hour day 1 , 15 , 29 . Beginning day 1 , patient undergo radiotherapy daily , 5 day week , 5.5 week . Patients also receive oral gefitinib daily day 1-365 . Treatment continue absence disease progression unacceptable toxicity Approximately 3-6 week completion chemoradiotherapy , patient evaluate . Some patient undergo surgical resection* possibly receive second course oxaliplatin ( IV 2 hour day 1 , 15 , 29 ) 4-8 week surgery . If surgery indicate , patient may receive additional course oxaliplatin . Cohorts 3-6 patient receive escalate dos oxaliplatin maximum tolerate dose determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive oxaliplatin , gefitinib , radiotherapy phase I MTD . Some patient either undergo surgical resection* and/or begin second course oxaliplatin phase I . NOTE : *Oral gefitinib discontinue ≥ 7 day surgery restart patient recover . Quality life assess baseline , 5-6 week , every 2-3 month 1 year . Patients follow every 2-3 month 1 year . PROJECTED ACCRUAL : Approximately 15-45 patient ( 3-12 phase I 12-33 phase II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma squamous cell carcinoma esophagus gastroesophageal ( GE ) junction Locally advance metastatic disease clinical staging , include esophagogastroduodenoscopy esophageal ultrasound Stage T2 , N0 disease beyond Bulk tumor must esophagus patient GE junction tumor Bronchoscopy require primary esophageal tumor &lt; 26 cm incisor No brain metastases PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy At least 4 month Hematopoietic WBC ≥ 3,000/mm^3 Granulocyte count ≥ 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin normal ALT AST ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Renal Not specify Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Pulmonary No clinically active interstitial lung disease Patients chronic stable asymptomatic radiographic change eligible Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod ( include barrier ) contraception 3 month study participation No peripheral neuropathy ≥ grade II No severe hypersensitivity gefitinib excipients No history allergy platinumbased compound antiemetic administer protocoldirected chemotherapy No active ongoing infection No uncontrolled illness No significant clinical disorder laboratory find would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent colonystimulating factor course 1 study therapy Chemotherapy More 4 week since prior chemotherapy Endocrine therapy Concurrent steroid therapy allow Radiotherapy More 4 week since prior radiotherapy Surgery Not specify Other More 30 day since prior nonapproved investigational drug No concurrent administration follow : Phenytoin Carbamazepine Rifampin Barbiturates Highlyactive antiretroviral therapy ( HAART ) Hypericum perforatum ( St. John 's wort ) No concurrent investigational agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
</DOC>